The scientific goal of the Cancer Biology program (CB) is to understand the molecular mechanisms that define normal and neoplastic cell growth in order to identify and characterize molecules, pathways and processes that are involved in tumor development, growth and progression. CB is a new program that represents the basic science initiatives of KUCC and is unified by member utilization of molecular, biochemical, and cell-based approaches that study the aberrant behavior of cancer cells. The overarching goal of CB is to catalyze collaborations that promote basic discoveries that can be translated from bench-to-bedside.
The Specific Aims of CB are 1) to promote collaboration that enhances discovery of the cellular, molecular and biochemical mechanisms that underlie tumor development, progression and malignant behavior;and 2) to leverage basic science discoveries to inspire pre-clinical and clinical development of novel cancer therapies. CB has 32 full members and 11 associate members, representing all KUCC institutions. Even at this early stage of KUCC growth, CB has garnered $17 million in cancer-related, peer-reviewed funding, of which $1.9 million was from NCI and $15.1 was from other peer-review sponsors. From 2006-2010, members published 250 cancer-relevant, peer-reviewed papers which were cited 2904 times (average 10.8 citations/publication) of which 7% were the result of inter-programmatic interactions and 15% from intra-programmatic interactions. In addition, CB program members accounted for 10.2% of the usage of the Biospecimen Shared Resource, 7.09% of the usage of the Biostatistics &Informatics Shared Resource, and 8.57% of the usage of the Lead Development &Optimization Shared Resource in 2010. CB is jointly led by Yvonne Wan and Linheng Li, who bring complementary scientific expertise, growing leadership experience, and diverse institutional representation. They will work closely with Danny R. Welch, Associate Director for Basic Science. CB has taken advantage of historical strengths at KUMC, KU-Lawrence and the Stowers Institute in liver, Gl, kidney and hematopoietic tumors. Recent recruitments have expanded those initiatives to include breast, HNSCC, and osteosarcoma research. In addition to a disease-based thematic organization, CB members have expertise that can be organized into four discipline-based themes - Chromatin Organization and Transcriptional Regulation, Signaling Pathways and Development, Cancer Cell Biology and Stem Cell Biology;and Cell Proliferation, Differentiation and Death,

Public Health Relevance

Collaborative, interdisciplinary, discovery-oriented basic cancer research will identify new targets that can be used for prognostic and therapeutic objectives. Further understanding of cancer will lead to introduction of new cancer drugs which will continue to have significant impact on the care, survival and quality of life of cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA168524-02
Application #
8557679
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$22,179
Indirect Cost
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Jiang, Yu; Simon, Steve; Mayo, Matthew S et al. (2015) Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors. Stat Med 34:613-29
Zeineldin, Maged; Jensen, Derek; Paranjape, Smita R et al. (2014) Human cancer xenografts in outbred nude mice can be confounded by polymorphisms in a modifier of tumorigenesis. Genetics 197:1365-76
Winham, Stacey J; Armasu, Sebastian M; Cicek, Mine S et al. (2014) Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. Genet Epidemiol 38:457-66
Block, Matthew S; Charbonneau, Bridget; Vierkant, Robert A et al. (2014) Variation in NF-?B signaling pathways and survival in invasive epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 23:1421-7
Pessetto, Ziyan Y; Ma, Yan; Hirst, Jeff J et al. (2014) Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. Mol Cancer Ther 13:2276-87
Purrington, Kristen S; Slager, Susan; Eccles, Diana et al. (2014) Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 35:1012-9
Bohl, Christopher R; Harihar, Sitaram; Denning, Warren L et al. (2014) Metastasis suppressors in breast cancers: mechanistic insights and clinical potential. J Mol Med (Berl) 92:13-30
Peterson, Kenneth R; Costa, Flávia C; Fedosyuk, Halyna et al. (2014) A cell-based high-throughput screen for novel chemical inducers of fetal hemoglobin for treatment of hemoglobinopathies. PLoS One 9:e107006
Meneely, Kathleen M; Luo, Qianyi; Riley, Andrew P et al. (2014) Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism. Bioorg Med Chem 22:5961-9
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256

Showing the most recent 10 out of 26 publications